In a significant boost for biotechnology innovation, Nuclera has successfully closed a $75 million financing round, aimed at advancing its groundbreaking eProtein Discovery platform. This Series C round was led by Elevage Medical Technologies and saw participation from various prominent investors, including Patient Square Capital, British Patient Capital, Cambridge Innovation Capital, and others. This substantial investment is set to enhance the commercialization efforts of Nuclera’s benchtop protein system, with a particular focus on expanding its reach in the US and Europe.
The innovative eProtein Discovery system is designed to streamline the processes of protein expression and purification within research laboratories. By automating construct screening and enabling rapid protein scale-up, Nuclera’s technology significantly reduces the time and costs associated with traditional methods. In less than 48 hours, researchers can now generate milligram quantities of proteins, a feat that typically takes months or even years. This is achieved through advanced techniques including digital microfluidics and cell-free protein synthesis, ensuring high-quality results at scale.
Nuclera’s technology is already making waves across various sectors, with installations in contract research organizations (CROs), biotech firms, and leading academic institutions such as University College London, University of Cambridge, and The Flanders Institute for Biotechnology in Belgium.
Dr. Michael Chen, CEO and co-founder of Nuclera, expressed his enthusiasm regarding the investment: “This significant funding illustrates the confidence in our team and our eProtein Discovery system. It will propel our mission to deliver benchtop protein screening solutions that empower scientists globally to efficiently produce proteins for drug discovery.”
Echoing this sentiment, Dr. Michael Wasserman, Chief Operating Officer of Elevage Medical Technologies, noted, “Nuclera has developed a solution for one of the leading obstacles in drug discovery: access to proteins. As the demand for quality proteins grows in the age of AI and structural biology, Nuclera’s technology is perfectly positioned to meet this need.”
A Promising Future for Protein Discovery
The implications of Nuclera’s advancements in protein production are profound. With the rise of AI in life sciences, the ability to rapidly produce customized proteins could significantly accelerate drug discovery timelines. This positions Nuclera at the forefront of a transformative shift in biotechnology, one that promises to enhance the efficiency and effectiveness of research.
Dr. Jonathan Milner, Chairman of Nuclera’s Board of Directors, emphasized the revolutionary potential of the eProtein Discovery system: “The ability to screen multiple protein expression profiles and print purified proteins in as little as 24 hours will not only revolutionize laboratory workflows but also have a demonstrable impact on research and drug discovery timelines.”
As the biotechnology landscape evolves, Nuclera’s focus on harnessing technology to simplify complex processes demonstrates its commitment to innovation. By addressing the critical need for rapid and reliable protein production, the company is poised to play a vital role in the future of life sciences.
In conclusion, Nuclera’s recent funding round not only underscores the trust investors place in its innovative technology but also highlights the company’s potential to significantly impact drug discovery. As the demand for efficient, high-quality protein production continues to rise, Nuclera stands ready to lead the charge in this essential field.
For further inquiries or corrections, please contact us at editor@thetimesmag.com.
